Please use this identifier to cite or link to this item:
https://hdl.handle.net/2440/8605
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Beller, E. | en |
dc.contributor.author | Tattersall, M. | en |
dc.contributor.author | Lumley, T. | en |
dc.contributor.author | Levi, J. A. | en |
dc.contributor.author | Dalley, D. | en |
dc.contributor.author | Olver, Ian N. | en |
dc.contributor.author | Page, J. | en |
dc.contributor.author | Abdi, E. | en |
dc.contributor.author | Wynne, C. | en |
dc.contributor.author | Friedlander, Michael | en |
dc.contributor.author | Boadle, D. | en |
dc.contributor.author | Wheeler, H. | en |
dc.contributor.author | Magrie, S. | en |
dc.contributor.author | Simes, R. J. | en |
dc.date.issued | 1997 | en |
dc.identifier.citation | Annals of Oncology, 1997; 8(3):277-283 | en |
dc.identifier.issn | 0923-7534 | en |
dc.identifier.uri | http://hdl.handle.net/2440/8605 | - |
dc.description.abstract | Purpose: To investigate the effect of two doses of megestrol acetate (MA) compared with placebo on quality of life (QoL) and nutritional status (NS) in patients with advanced endo crine-insensitive cancer. Patients and methods: Two hundred forty patients were randomised to double-blind MA 480 mg/day, MA 160 mg/day, or matching placebo for 12 weeks. Nutritional status (including weight, skinfold thickness and midarm circumference) and QoL (using 6 linear analogue self-assessment (LASA) scales) were assessed at randomisation and after four, eight and 12 weeks. A QoL ranking incorporating QoL and death was also used ranging from 1 = dead to 5 = much better QoL. Results: One hundred seventy-four patients were assessable at week four, 136 at week eight and 103 patients at week 12. Patients receiving MA reported substantially better appetite (P = 0.001), mood (P = 0.001) and overall quality of life (P < 0.001), and possibly less nausea and vomiting (P = 0.08) than patients receiving placebo, based on a test for trend. A larger benefit was seen with the higher dose which (unlike the lower dose) was significantly better in pairwise comparisons with placebo for appetite, mood and overall QoL (each P ≤0.001). Despite some missing data on QoL scores, QoL ranking was available on 227 (95%) of patients with significantly higher QoL ranking associated with MA (P =0.002). Improve ments in QoL occurred early within four weeks and were sustained. No statistically significant differences were observed in NS measurements, including weight (P =0.29). Side effects of therapy were minor and did not differ significantly across treatments. Conclusion: Megestrol acetate given at 480 mg/day is useful palliation in patients with endocrine-insensitive advanced cancer. It improves appetite, mood and overall quality of life in these patients, although not through a direct effect on nutritional status. | en |
dc.description.statementofresponsibility | E. Beller, M. Tattersall, T. Lumley, J. Levi, D. Dalley, I. Olver, J. Page, E. Abdi, C. Wynne, M. Friedlander, D. Boadle, H. Wheeler, S. Margrie, R. J. Simes, and Australasian Megestrol Acetate Cooperative Study Group | en |
dc.language.iso | en | en |
dc.rights | © 1997 Kluwer Academic Publishers | en |
dc.subject | cachexia; megestrol acetate; quality of life | en |
dc.title | Improved quality of life with megasterol acetate in patients with endocrine-insensitive advanced cancer. | en |
dc.type | Journal article | en |
Appears in Collections: | Medicine publications |
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.